Treatment
Tislelizumab Combined With Chemotherapy clinical trials
We’re tracking 80 recruiting studies that include Tislelizumab Combined With Chemotherapy, each written for real people, not researchers, below.
Recruiting studies
- NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT05981703RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT07059299RecruitingPhase 1
Immunotherapy plus chemo before stomach/esophagus cancer surgery
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
FrankfurtAges 18 years+ - NCT06333561Recruiting
Combination therapy for infiltrative liver cancer
This trial tests a three-drug combination for a specific type of liver cancer called infiltrative hepatocellular carcinoma. It combines a liver-directed chemotherapy infusion (HAIC) with two oral and intravenous drugs (lenvatinib and a PD-1 inhibitor) to see if it works better than lenvatinib alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT06725498RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06709885RecruitingPhase 2
HDAC inhibitor with chemoimmunotherapy before colon cancer surgery
This trial tests adding an HDAC inhibitor to standard chemotherapy and immunotherapy before surgery for a type of colon cancer called pMMR that has grown into nearby fat or deeper. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06838910RecruitingPhase 2
Tislelizumab and anlotinib for thymus cancer after first treatment
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07609121RecruitingPhase 2
Radiation, Chemotherapy, and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07089199RecruitingPhase 2
Drug combo before surgery for stage III lung cancer
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
Jinan, ShandongAges 18–75 - NCT07450040Enrolling by invitation
Tislelizumab plus chemo for early-stage NK/T-cell lymphoma
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Shanghai, ChinaAges 18–70 - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT06354140RecruitingPhase 2
Tislelizumab plus S-1 for esophageal cancer after surgery
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07244016Recruiting
TCR test to guide immunotherapy and chemo for extensive SCLC
This trial tests whether a blood test (TCR) can help predict how well a combination of the immunotherapy drug tislelizumab and chemotherapy works for people with extensive-stage small cell lung cancer (SCLC) that has not been treated before.
Zhengzhou, HenanAges 18 years+ - NCT07667751RecruitingPhase 2
Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
HefeiAges 18–75 - NCT07662395RecruitingPhase 2/Phase 3
New drug plus chemo for advanced squamous lung cancer
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07317609RecruitingPhase 1
Immunotherapy plus chemo before endoscopic resection for esophageal cancer
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06646588RecruitingPhase 2
Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT06032845RecruitingPhase 2
Freezing tumors plus immunotherapy for advanced solid tumors
This trial tests if freezing tumor cells (cryoablation) combined with two drugs (tislelizumab and lenvatinib) can help people whose solid tumors have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+
Common questions
- Are there clinical trials studying Tislelizumab Combined With Chemotherapy?
- Yes. Clin2 currently lists 80 recruiting studies that include Tislelizumab Combined With Chemotherapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tislelizumab Combined With Chemotherapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tislelizumab Combined With Chemotherapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tislelizumab Combined With Chemotherapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.